NO20050419L - Farmasoytiske blandinger av legemidler og polymerer av halv-orden - Google Patents

Farmasoytiske blandinger av legemidler og polymerer av halv-orden

Info

Publication number
NO20050419L
NO20050419L NO20050419A NO20050419A NO20050419L NO 20050419 L NO20050419 L NO 20050419L NO 20050419 A NO20050419 A NO 20050419A NO 20050419 A NO20050419 A NO 20050419A NO 20050419 L NO20050419 L NO 20050419L
Authority
NO
Norway
Prior art keywords
polymers
pharmaceutical mixtures
drugs
order drugs
order
Prior art date
Application number
NO20050419A
Other languages
English (en)
Norwegian (no)
Inventor
Walter Christian Babcock
Ravi Mysore Shanker
Daniel Tod Smithey
Marshall David Crew
Dwayne Thomas Friesen
William Brett Caldwell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31715934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050419(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20050419L publication Critical patent/NO20050419L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050419A 2002-08-12 2005-01-25 Farmasoytiske blandinger av legemidler og polymerer av halv-orden NO20050419L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40308702P 2002-08-12 2002-08-12
PCT/IB2003/003465 WO2004014342A1 (fr) 2002-08-12 2003-07-31 Compositions pharmaceutiques de medicaments partiellement ordonnes et de polymeres

Publications (1)

Publication Number Publication Date
NO20050419L true NO20050419L (no) 2005-04-04

Family

ID=31715934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050419A NO20050419L (no) 2002-08-12 2005-01-25 Farmasoytiske blandinger av legemidler og polymerer av halv-orden

Country Status (24)

Country Link
US (2) US8257739B2 (fr)
EP (2) EP1530457B1 (fr)
JP (1) JP2006500349A (fr)
CN (1) CN1681479A (fr)
AR (1) AR040969A1 (fr)
AT (1) ATE442130T1 (fr)
AU (1) AU2003249474A1 (fr)
BR (1) BR0313428A (fr)
CA (1) CA2496441C (fr)
DE (1) DE60329188D1 (fr)
ES (1) ES2333318T3 (fr)
GT (1) GT200300170A (fr)
IL (1) IL166411A0 (fr)
MX (1) MXPA05000977A (fr)
NO (1) NO20050419L (fr)
PA (1) PA8579801A1 (fr)
PE (1) PE20040865A1 (fr)
PL (1) PL375345A1 (fr)
PT (1) PT1530457E (fr)
RU (1) RU2005103625A (fr)
TW (1) TW200406224A (fr)
UY (1) UY27929A1 (fr)
WO (1) WO2004014342A1 (fr)
ZA (1) ZA200500470B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2577852A1 (fr) 2004-08-31 2006-03-09 Pfizer Products Inc. Posologies pharmaceutiques comportant un medicament a faible solubilite et un polymere
WO2006079921A2 (fr) 2005-01-28 2006-08-03 Pfizer Products Inc. Deshydratation de particules contenant un medicament
PT2043610E (pt) 2006-07-21 2015-10-22 Bend Res Inc Secagem de partículas contendo fármacos
EP2140883B1 (fr) * 2007-04-20 2012-10-31 Daido Chemical Corporation Nouvelle base pour dispersion solide sèche, dispersion solide contenant la base et composition contenant la dispersion
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2366378A1 (fr) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Formulations de donépézil à libération prolongée
MX2013010306A (es) 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
TW201311240A (zh) * 2011-07-21 2013-03-16 必治妥美雅史谷比公司 非晶形哌啶基化合物之生物可利用組合物
CN105025887B (zh) 2013-03-07 2017-07-28 陶氏环球技术有限责任公司 新颖极低粘度酯化纤维素醚
WO2014137779A1 (fr) 2013-03-07 2014-09-12 Dow Global Technologies Llc Nouveaux éthers de cellulose estérifiés de très haut poids moléculaire
CN105899542B (zh) 2013-03-07 2018-08-03 陶氏环球技术有限责任公司 新颖低粘度酯化纤维素醚
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2832723B1 (fr) * 2013-07-29 2017-02-15 Zentiva, a.s. Formes amorphes stabilisées de la Saxagliptine
WO2015023710A1 (fr) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
EP3212169B1 (fr) 2014-10-31 2021-01-13 Bend Research, Inc. Procédé de formation de domaines actifs dispersés dans une matrice

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JPS6314724A (ja) * 1986-07-08 1988-01-21 Tooa Eiyoo Kk プラゾシン製剤
JPH02149518A (ja) * 1988-11-30 1990-06-08 Nikken Chem Co Ltd 経口投与用薬剤
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140185C2 (de) 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
US5876754A (en) 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE4316537A1 (de) 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
JP3345761B2 (ja) * 1993-06-16 2002-11-18 日本特殊陶業株式会社 ヒーター付スパークプラグ及びその製造方法
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE4329446A1 (de) 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5685331A (en) 1994-12-20 1997-11-11 Ac & R Components, Inc. Oil level regulator
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
WO1997013503A1 (fr) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthese de nanoparticules medicamenteuses par sechage par pulverisation
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
JPH09309828A (ja) * 1996-03-18 1997-12-02 Eisai Co Ltd 溶解を改善した薬剤組成物
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CN1248968A (zh) 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US6126451A (en) 1997-06-02 2000-10-03 Compaq Computer Corporation SCSI connector
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
KR100385529B1 (ko) 1998-02-05 2003-05-27 화이자 프로덕츠 인코포레이티드 신규 디하이드록시헥산산 유도체
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
CA2395331C (fr) * 1999-12-23 2009-01-06 Pfizer Products Inc. Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
BR0210520A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
EP1448174A2 (fr) 2001-09-28 2004-08-25 Solubest Ltd Nanoparticules solubles dans l'eau constituees de principes actifs hydrophiles et hydrophobes
US6848693B2 (en) * 2001-11-20 2005-02-01 Actuant Corporation Pseudo four-leg vehicle leveling system with independent leg lock-out
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
BRPI0417492A (pt) 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv

Also Published As

Publication number Publication date
CA2496441A1 (fr) 2004-02-19
WO2004014342A1 (fr) 2004-02-19
UY27929A1 (es) 2004-03-31
RU2005103625A (ru) 2005-08-20
IL166411A0 (en) 2006-01-15
PE20040865A1 (es) 2004-11-25
EP2111856A2 (fr) 2009-10-28
TW200406224A (en) 2004-05-01
US8491933B2 (en) 2013-07-23
BR0313428A (pt) 2005-06-28
EP2111856A3 (fr) 2014-09-10
DE60329188D1 (de) 2009-10-22
EP1530457B1 (fr) 2009-09-09
CA2496441C (fr) 2010-03-16
PT1530457E (pt) 2009-11-06
EP1530457A1 (fr) 2005-05-18
PL375345A1 (en) 2005-11-28
PA8579801A1 (es) 2004-02-16
AU2003249474A1 (en) 2004-02-25
US20040156905A1 (en) 2004-08-12
MXPA05000977A (es) 2005-05-16
US20120322805A1 (en) 2012-12-20
AR040969A1 (es) 2005-04-27
GT200300170A (es) 2004-05-12
ZA200500470B (en) 2006-07-26
JP2006500349A (ja) 2006-01-05
US8257739B2 (en) 2012-09-04
CN1681479A (zh) 2005-10-12
ATE442130T1 (de) 2009-09-15
ES2333318T3 (es) 2010-02-19

Similar Documents

Publication Publication Date Title
NO20050419L (no) Farmasoytiske blandinger av legemidler og polymerer av halv-orden
CY1112268T1 (el) Σκευασμα δισκιου παρατεταμενης αποδεσμευσης περιεχον πραμιπεξολη ή ενα φαρμακευτικως αποδεκτο αλας αυτης
BR0210518A (pt) Composições farmacêuticas de dispersões de drogas e polìmeros neutros
DK1543063T3 (da) Medikament levering
NO20081574L (no) Anvendelse av IL-23- og IL-17-antagonister for behandling av autoimmun, okulaer, inflammatorisk sykdom
NO20064570L (no) Farmasoytiske preparater
DE602004020583D1 (de) Komprimierte kaugummitablette
WO2006034367A3 (fr) Procedes et systemes de prevention de diversion de medicaments sur ordonnance
ATE412387T1 (de) Medizinische vorrichtungen
NO20053150D0 (no) System for administrasjon av medisin.
MA28512B1 (fr) Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
ECSP088555A (es) Composiciones farmacéuticas
WO2007149804A3 (fr) Dérivés de polymères de lactame
CL2004000838A1 (es) Uso de un antagonista del receptor de aldosterona y un agente antiobesidad para preparar un medicamento util en el tratamiento de una condicion relacionada al sistema cardiovascular.
BRPI0418294A (pt) composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
DK1220852T3 (da) Substituerede diazepaner
DE60321572D1 (de) Transdermales arzneimittelverabreichungssystem
WO2004014943A3 (fr) Composes, et leurs applications analgesiques
TW200624464A (en) Amphiphilic block copolymer and pharmaceutical formulation comprising the same
NO20075508L (no) Stannsoporfinpreparater og administrering
NO20043841L (no) 1-fenyl-2-heteroaryl-substituerte benzimidazolderivater, anvendelsen derav for fremstilling av legemidler benyttet i behandlingen av immunologiske sykdommer
DK2231131T3 (da) Formuleringer af organiske platinforbindelser i tilstedeværelsen af associative polymerer, således opnåede produkter og anvendelser deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application